Compounds > ahr 5850
Page last updated: 2024-11-13

ahr 5850

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sodium (2-amino-3-benzoylphenyl)acetate : An organic sodium salt having amfenac(1-) as the counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23665728
CHEMBL ID435759
CHEBI ID75918
SCHEMBL ID9644552
MeSH IDM0062716

Synonyms (40)

Synonym
amfenac sodium
phenazox
sodium 2-amino-3-benzoylbenzeneacetate
sodium (2-amino-3-benzoylphenyl)acetate
ahr 5850
benzeneacetic acid, 2-amino-3-benzoyl-, monosodium salt
ahr 5850d
CHEMBL435759
chebi:75918 ,
ahr-5850
amfenac sodium anhydrous
61941-56-8
sodium 2-(2-amino-3-benzoyl-phenyl)acetate;amfenac sodium monohydrate
A833336
NCGC00184993-01
NCGC00184993-02
dtxsid8048658 ,
dtxcid5028584
tox21_113016
cas-61941-56-8
tox21_113017
AKOS015920452
c20288ewag ,
unii-c20288ewag
sodium 2-(2-amino-3-benzoylphenyl)acetate
benzeneacetic acid, 2-amino-3-benzoyl-, sodium salt (1:1)
benzeneacetic acid, 2-amino-3-benzoyl-, sodium salt
amfenac sodium [who-dd]
SCHEMBL9644552
Q27145633
FT-0727449
sodium2-(2-amino-3-benzoylphenyl)acetate
sodium [2-amino-3-(phenylcarbonyl)phenyl]acetate
desbromo bromfenac impurity
bdbm50224285
amfenac sodium salt;sodium 2-(2-amino-3-benzoylphenyl)acetate
BCP33620
mfcd09842317
sodium;2-(2-amino-3-benzoylphenyl)acetate
A868592

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
cyclooxygenase 1 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency19.74330.000221.22318,912.5098AID743036; AID743053
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.20020.000229.305416,493.5996AID743069; AID743075; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.73070.001019.414170.9645AID743094; AID743140
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin-H2 D-isomeraseMus musculus (house mouse)IC50 (µMol)0.20000.07000.53401.1000AID160886
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)0.20000.00051.41288.2000AID160707; AID160886
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)0.20000.00050.57393.4000AID160707; AID160886
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)0.10000.00291.786810.0000AID161308
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.10000.00291.823210.0000AID161308
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmProstaglandin-H2 D-isomeraseMus musculus (house mouse)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID190326Potency in adjuvant-induced arthritis assay/ potency in intestinal toxicity assay.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID1130688Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as potency in adjuvant injected foot treated po once daily on days 18 to 22 and 28 to 28 relative to phenylbutazone1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID187727Evaluated for the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 4.0 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID1130686Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.0031 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID186645Evaluated for chronic intestinal toxicity (multiple oral dose) in rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID170707Percent change of the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 4.0 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID1130698Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 4 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID1130682Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID1130673Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant injected foot at 0.0316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID1130697Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 0.8 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID1130704Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant injected foot at 0.316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID171870Antiinflammatory activity was tested in Pleural effusion rate assay and the percent change in average volume of pleural fluid at indomethacin dose of 4.0 mg/kg. 1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID1130675Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant uninjected foot at 0.316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID114055Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 5 hours following oral administration1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID172732Percent activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 0.16 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID212537Pharmacological potency relative to indomethacin for prodrug candidate by intestinal toxicity assay.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID160707Inhibition of prostaglandin G/H synthase obtained from bovine seminal vesicles.1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1130689Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as potency in adjuvant uninjected foot treated po once daily on days 18 to 22 and 28 to 28 relative to phenylbutazone1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID188026Pharmacological potency relative to indomethacin for prodrug candidate by adjuvant-induced arthritis assay1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID172888Percent change in average volume of pleural fluid at a dose 4 mg/kg of indomethacin and 5-h response is evaluated by Evans blue-carrageenan induced pleural effusion assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID160886Evaluated for the inhibition of prostaglandin synthetase obtained from bovine seminal vesicles at the dose of 4.0 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID179690Acute gastric toxicity (single oral dose) in male fasted rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID172889Percent change in avg. volume of pleural fluid at a dose of 0.16 mg/kg and 5-h response is evaluated by Evans blue-carrageenan induced pleural effusion assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID188015Evaluated for chronic potency in adjuvant arthritis assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1130672Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant injected foot at 0.0031 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID170704Percent change of the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 0.8 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID187724Evaluated for the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 0.8 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID187723Evaluated for the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 0.16 mg/kg (p.o.)1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Antiinflammatory agents. 2. Syntheses and antiinflammatory activity of substituted 2-aminophenylacetic acid derivatives.
AID188014Evaluated for acute potency in pleural effusion assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1130679Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant uninjected foot at 0.0031 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID1130687Toxicity in adjuvant-induced arthritis Lewis Wistar rat model assessed as change in 11 day weight at 0.0316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID171873Antiinflammatory activity was tested in pleural effusion rate assay and the percent change in average volume of pleural fluid at the dose of 4.0 mg/kg1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID172892Percent change in average volume of pleural fluid at a dose of 4.0 mg/kg and 5-h response by Evans blue-carrageenan induced pleural effusion assay.1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID161308Inhibitory activity against Prostaglandin G/H synthase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID114054Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 20 min following oral administration1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1130680Antiinflammatory activity against adjuvant-induced arthritis in Lewis Wistar rat assessed as change in 11 day edema volume in adjuvant uninjected foot at 0.0316 mg/kg, po treated once daily on days 18 to 22 and 28 to 281979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.
AID172890Percent change in average volume of pleural fluid at a dose of 100 mg/kg and 5-h response by Evans blue-carrageenan induced pleural effusion assay.1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID171871Antiinflammatory activity was tested in Pleural effusion rate assay and the percent change in average volume of pleural fluid at the dose of 100 mg/kg1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.10 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amfenac
amfenac: RN given refers to parent cpd; structure. amfenac : An oxo monocarboxylic acid that is benzophenone in which one of the phenyl groups is substituted by an amino group and a carboxymethyl group at position 2 and 3, respectively. The corresponding carboxamide, nepafenac, is a prodrug of amfenac and is used for the treatment of pain and inflammation following cataract surgery.		1.9510amino acid;
benzophenones;
oxo monocarboxylic acid;
primary amino compound;
substituted aniline		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		1.9510benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.6630aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9510pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
zomepirac
zomepirac: RN given refers to parent cpd; structure		1.9610aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
nepafenac
nepafenac: amide analog of amfenac; structure in first source. nepafenac : A monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery.		1.9710monocarboxylic acid amidecyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		02.6530
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		02.3620
Cholera Infantum
[description not available]		01.9710
Innate Inflammatory Response
[description not available]		01.9710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9710